Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 16,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Recruiting No phase listed Observational

Multi-center MRD Registry for Inflammatory Breast Cancer

NCT06966050
View directory record Official record
Conditions
Breast Cancer
Interventions
Quality-of-life Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

NCT00005635
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

NCT04294225
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Anastrozole, Letrozole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

NCT00034125
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY353381, tamoxifen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Miami, Florida • Shreveport, Louisiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 28, 2026, 1:03 PM EDT
Completed No phase listed Observational

An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.

NCT00440817
View directory record Official record
Conditions
Lymphoma
Interventions
No intervention
Other
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Highland Park, Illinois • Wichita, Kansas • Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 28, 2026, 1:03 PM EDT
Terminated No phase listed Observational

Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics

NCT01675674
View directory record Official record
Conditions
Mucopolysaccharidoses, Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis IV, Mucopolysaccharidosis VI
Interventions
Dried blood spot test for MPS
Other
Lead sponsor
National MPS Society
Other
Eligibility
6 Months to 18 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 28, 2026, 1:03 PM EDT
Recruiting Phase 1 Interventional

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

NCT05627960
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
Interventions
AG-01 Compound
Drug
Lead sponsor
A&G Pharmaceutical Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT03021460
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

NCT02347176
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Yoga for Aromatase Inhibitor-associated Joint Pain

NCT01951976
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaires, Yoga Classes
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 28, 2026, 1:03 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240
View directory record Official record
Conditions
Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 63 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

NCT00912418
View directory record Official record
Conditions
Melanoma
Interventions
autologous tumor cells plus GM-CSF-in Adjuvant
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 28, 2026, 1:03 PM EDT
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

NCT02610413
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

NCT03488108
View directory record Official record
Conditions
Alopecia
Interventions
Platelet Rich Plasma, Minoxidil Foam
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 28, 2026, 1:03 PM EDT
Completed No phase listed Observational

Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery

NCT00776308
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 28, 2026, 1:03 PM EDT
Completed No phase listed Observational

Genetics and Heart Health After Cancer Therapy

NCT03510689
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, Brca2), Heart Diseases, Drug-Induced Cardiomyopathy
Interventions
echocardiography, Cardiopulmonary Exercise Testing, Blood Collection
Diagnostic Test · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Patients With Erythematous Rosacea

NCT01186068
View directory record Official record
Conditions
Erythematous (Type One) Rosacea
Interventions
V-101, vehicle
Drug · Other
Lead sponsor
Vicept Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
San Diego, California • Miami Beach, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 28, 2026, 1:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia

NCT01125150
View directory record Official record
Conditions
Acanthosis Nigricans, Hyperinsulinemia, Spectroscopic Analysis
Interventions
Metformin, Dietary Modification
Drug · Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
11 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 28, 2026, 1:03 PM EDT
Completed No phase listed Observational

Interpolated Flap Study

NCT04164550
View directory record Official record
Conditions
Skin Cancer, Non-Melanoma, Skin Cancer Melanoma, Mohs Micrographic Surgery
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 28, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Topical Agent for Treatment of Red Skin

NCT00279890
View directory record Official record
Conditions
Rosacea, Bilaterally Symmetric Red Skin on Cheeks
Interventions
Topical SR-01
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Oct 28, 2026, 1:03 PM EDT
Terminated Phase 1 Interventional

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560
View directory record Official record
Conditions
Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product, Trastuzumab
Biological · Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 28, 2026, 1:03 PM EDT
Terminated Not applicable Interventional

Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis

NCT01286220
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
Dilute bleach baths, Water
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 28, 2026, 1:03 PM EDT